Early versus standard antiretroviral therapy for HIV-infected adults in Haiti

New England Journal of Medicine

Volumn 363, Issue 3, 2010, Pages 257-265

  Severe, Patrice ^a   Juste, Marc Antoine Jean ^a   Ambroise, Alex ^a   Eliacin, Ludger ^a   Marchand, Claudel ^a   Apollon, Sandra ^a   Edwards, Alison ^b   Bang, Heejung ^b   Nicotera, Janet ^c   Godfrey, Catherine ^d   Gulick, Roy M ^b   Johnson Jr , Warren D ^b   Pape, Jean William ^a,b   Fitzgerald, Daniel W ^b  

^a Department of Adolescent Medicine   (Haïti)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; LOPINAVIR; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; BEDTIME DOSAGE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HAITI; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TUBERCULOSIS;

EID: 77954630522     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0910370     Document Type: Article

References (33)

1. Scaling up antiretroviral therapy in resource-limited settings. Geneva: World Health Organization. 2004.
2. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2006 revision. Geneva: World Health Organization, 2006.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services, November 3, 2008. (Accessed April 5, 2010, at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.)
4. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-70.
5. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe. Paris: EACS. (Accessed April 5, 2010, at http://www.europeanaidsclinicalsociety.org/ guidelines.asp.)
6. Treatment of HIV-1 infected adults with antiretroviral therapy. London: British HIV Association, 2008. (Accessed April 5, 2010, at http://www.bhiva.org/ cms1222226.asp.)
7. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005; 353:2325-34.
8. Leger P, Charles M, Severe P, Riviere C, Pape JW, Fitzgerald DW. 5-Year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med 2009;361:828-9.
9. Peck R, Fitzgerald DW, Liautaud B, et al. The feasibility, demand, and effect of integrating primary care services with HIV voluntary counseling and testing: evaluation of a 15-year experience in Haiti, 1985-2000. J Acquir Immune Defic Syndr 2003;33:470-5.
10. WHO case definitions for AIDS surveillance in adults and adolescents. Wkly Epidemiol Rec 1994;69:273-5.
11. Fitzgerald DW, Marotte C, Verdier RI, Johnson WD Jr, Pape JW. Comprehension during informed consent in a less-developed country. Lancet 2002;360:1301-2. (Pubitemid 35284623)
12. Anglaret X, Chêne G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999;353:1463-8.
13. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS 2005;19: 1299-308.
14. Pape JW, Jean S, Ho J, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342:268-72. (Pubitemid 23224420)
15. Fawzi WW, Msamanga GI, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004;351:23-32. (Pubitemid 38857244)
16. Burgess AL, Fitzgerald DW, Severe P, et al. Integration of tuberculosis screening at an HIV voluntary counseling and testing centre in Haiti. AIDS 2001;15:1875-9. (Pubitemid 32939250)
17. Treatment of tuberculosis: guidelines for national programmes. Geneva: World Health Organization, 2003.
18. Treatment of tuberculosis. MMWR Recomm Rep 2003;52(RR11):1-77. [Erratum, MMWR Recomm Rep 2005;53:1203.]
19. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2006.
20. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000;356:1470-4.
21. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care 2000;12:255-66.
22. Division of AIDS, Regulatory Compliance Center. Manual for grading the severity of adult and pediatric adverse events. Bethesda, MD: DAIDS/RCC, 2009. (Accessed April 5, 2010, at http://rcc.tech-res.com/safetyandpharmacovigilance/. )
23. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
24. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. 2nd ed. New York: Springer, 2003.
25. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360:1815-26.
26. When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;373:1352-63.
27. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009;23:1717-25.
28. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359:2059-64. (Pubitemid 34680968)
29. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005;19:2109-16. (Pubitemid 41668999)
30. Global tuberculosis control 2009: epidemiology, strategy, financing. Geneva: World Health Organization, 2009.
31. Nunn P, Reid A, De Cock KM. Tuberculosis and HIV infection: the global setting. J Infect Dis 2007;196:Suppl 1:S5-S14.
32. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006;368: 505-10. (Pubitemid 44142772)
33. Walensky RP, Wolf LL, Wood R, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009;151:157-66.